CYNK-101

N/A

Report date: 2025/03/27 16:54:38

Base Information

Drug NameCYNK-101

Drug Alias NameCYNK-101

ClassificationCell and gene therapy > Cell therapy > Source of cells > Placenta-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Source of cells > Hematopoietic stem cell-derived

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCelularity Inc

China Registration ClassN/A

Develop Information

Active CompaniesCelularity Inc

Inactive CompaniesN/A

Active IndicationsStomach NeoplasmsLymphoma

Inactive IndicationsEsophageal Neoplasms

Other Information

ATC CodeN/A